Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Soft Tissue Neoplasms | 15 | 2024 | 1163 | 4.370 |
Why?
|
Salivary Gland Neoplasms | 17 | 2024 | 305 | 3.520 |
Why?
|
Myoepithelioma | 5 | 2020 | 26 | 2.730 |
Why?
|
Biopsy, Fine-Needle | 19 | 2024 | 1130 | 2.310 |
Why?
|
Immunohistochemistry | 31 | 2024 | 11030 | 2.070 |
Why?
|
RNA-Binding Protein EWS | 5 | 2023 | 211 | 1.890 |
Why?
|
Paranasal Sinus Neoplasms | 6 | 2024 | 243 | 1.880 |
Why?
|
Head and Neck Neoplasms | 15 | 2023 | 2924 | 1.710 |
Why?
|
Cytodiagnosis | 5 | 2019 | 450 | 1.590 |
Why?
|
Neurilemmoma | 4 | 2019 | 522 | 1.560 |
Why?
|
Epithelioid Cells | 3 | 2019 | 61 | 1.490 |
Why?
|
Nose Neoplasms | 5 | 2024 | 249 | 1.360 |
Why?
|
Liposarcoma | 4 | 2021 | 288 | 1.300 |
Why?
|
Gene Rearrangement | 7 | 2023 | 1143 | 1.270 |
Why?
|
Gene Fusion | 5 | 2021 | 357 | 1.270 |
Why?
|
Carcinoma | 9 | 2023 | 2311 | 1.210 |
Why?
|
Maxillary Sinus Neoplasms | 2 | 2018 | 38 | 1.140 |
Why?
|
Sarcoma | 7 | 2023 | 1799 | 1.110 |
Why?
|
Carcinoma, Acinar Cell | 3 | 2023 | 62 | 1.040 |
Why?
|
Diagnosis, Differential | 24 | 2024 | 12973 | 1.040 |
Why?
|
Carcinoma, Ductal | 3 | 2024 | 97 | 0.880 |
Why?
|
In Situ Hybridization, Fluorescence | 15 | 2023 | 2510 | 0.870 |
Why?
|
Receptors, Steroid | 2 | 2023 | 155 | 0.870 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2023 | 1609 | 0.860 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2021 | 68 | 0.860 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 1637 | 0.820 |
Why?
|
Nevus, Blue | 1 | 2022 | 43 | 0.800 |
Why?
|
Thyroid Gland | 6 | 2019 | 1168 | 0.760 |
Why?
|
Skin Neoplasms | 7 | 2024 | 5836 | 0.750 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2018 | 954 | 0.740 |
Why?
|
beta Catenin | 2 | 2016 | 1046 | 0.730 |
Why?
|
Receptors, Thyroid Hormone | 2 | 2023 | 202 | 0.720 |
Why?
|
Salivary Glands | 5 | 2023 | 231 | 0.710 |
Why?
|
Carcinoma, Adenoid Cystic | 6 | 2021 | 261 | 0.680 |
Why?
|
Fibroma | 2 | 2020 | 197 | 0.670 |
Why?
|
Sarcoma, Small Cell | 2 | 2018 | 17 | 0.670 |
Why?
|
Homeodomain Proteins | 2 | 2019 | 2430 | 0.660 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2019 | 12 | 0.640 |
Why?
|
Uveal Neoplasms | 1 | 2022 | 343 | 0.640 |
Why?
|
Rhabdomyoma | 2 | 2022 | 56 | 0.630 |
Why?
|
Mesenchymoma | 1 | 2019 | 50 | 0.630 |
Why?
|
Cytogenetic Analysis | 2 | 2018 | 270 | 0.600 |
Why?
|
Adenoma, Oxyphilic | 3 | 2019 | 150 | 0.600 |
Why?
|
Terminology as Topic | 3 | 2016 | 1536 | 0.600 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7423 | 0.590 |
Why?
|
Papillomaviridae | 4 | 2020 | 1137 | 0.590 |
Why?
|
Chondroma | 1 | 2018 | 53 | 0.590 |
Why?
|
Immunophenotyping | 4 | 2023 | 1865 | 0.580 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2019 | 169 | 0.580 |
Why?
|
In Situ Hybridization | 2 | 2019 | 1885 | 0.560 |
Why?
|
Skull Neoplasms | 1 | 2018 | 173 | 0.550 |
Why?
|
Facial Bones | 1 | 2018 | 209 | 0.540 |
Why?
|
Fibrosarcoma | 1 | 2018 | 312 | 0.540 |
Why?
|
Pelvic Neoplasms | 1 | 2018 | 248 | 0.540 |
Why?
|
Myofibroma | 1 | 2016 | 45 | 0.530 |
Why?
|
Biopsy | 6 | 2020 | 6766 | 0.520 |
Why?
|
Thyroid Neoplasms | 7 | 2019 | 2354 | 0.520 |
Why?
|
Pleural Effusion, Malignant | 2 | 2014 | 108 | 0.520 |
Why?
|
Hemangiopericytoma | 1 | 2016 | 71 | 0.510 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2018 | 501 | 0.510 |
Why?
|
Mouth Neoplasms | 4 | 2024 | 594 | 0.510 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2018 | 340 | 0.500 |
Why?
|
World Health Organization | 3 | 2022 | 1326 | 0.500 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2015 | 34 | 0.490 |
Why?
|
Adenocarcinoma | 6 | 2020 | 6360 | 0.480 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 93 | 0.470 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2019 | 3661 | 0.470 |
Why?
|
Pathology, Clinical | 1 | 2018 | 374 | 0.470 |
Why?
|
Nasal Cavity | 2 | 2022 | 309 | 0.470 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2024 | 4044 | 0.470 |
Why?
|
S100 Proteins | 1 | 2015 | 214 | 0.460 |
Why?
|
Pericytes | 1 | 2016 | 299 | 0.440 |
Why?
|
Fetal Proteins | 1 | 2014 | 99 | 0.440 |
Why?
|
Adenoma, Pleomorphic | 3 | 2020 | 77 | 0.420 |
Why?
|
DNA-Binding Proteins | 7 | 2024 | 9600 | 0.420 |
Why?
|
Humans | 102 | 2024 | 765926 | 0.410 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 2024 | 57 | 0.410 |
Why?
|
Gene Silencing | 1 | 2019 | 1504 | 0.410 |
Why?
|
Thyroid Nodule | 3 | 2019 | 765 | 0.410 |
Why?
|
Aged | 44 | 2024 | 171163 | 0.400 |
Why?
|
Zebrafish Proteins | 1 | 2018 | 1017 | 0.390 |
Why?
|
Middle Aged | 49 | 2024 | 223016 | 0.380 |
Why?
|
Adult | 49 | 2024 | 223088 | 0.380 |
Why?
|
T-Box Domain Proteins | 1 | 2014 | 469 | 0.370 |
Why?
|
RNA, Viral | 1 | 2019 | 2866 | 0.360 |
Why?
|
Chordoma | 1 | 2014 | 343 | 0.360 |
Why?
|
Oropharyngeal Neoplasms | 4 | 2022 | 492 | 0.360 |
Why?
|
Precancerous Conditions | 3 | 2024 | 975 | 0.350 |
Why?
|
Young Adult | 25 | 2022 | 59857 | 0.350 |
Why?
|
Aged, 80 and over | 27 | 2024 | 59496 | 0.350 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2019 | 702 | 0.340 |
Why?
|
Male | 58 | 2024 | 363815 | 0.340 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2020 | 2176 | 0.330 |
Why?
|
Carcinoma, Papillary | 2 | 2018 | 786 | 0.330 |
Why?
|
Mutation | 8 | 2024 | 30192 | 0.320 |
Why?
|
Female | 56 | 2024 | 396141 | 0.310 |
Why?
|
Bone Neoplasms | 3 | 2016 | 2559 | 0.310 |
Why?
|
Rhabdomyosarcoma | 1 | 2011 | 354 | 0.310 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2021 | 287 | 0.310 |
Why?
|
Sensitivity and Specificity | 7 | 2020 | 14643 | 0.290 |
Why?
|
Mesothelioma | 1 | 2014 | 774 | 0.290 |
Why?
|
Melanoma | 3 | 2022 | 5695 | 0.290 |
Why?
|
Testicular Neoplasms | 1 | 2013 | 800 | 0.280 |
Why?
|
Carcinoma, Small Cell | 3 | 2018 | 420 | 0.280 |
Why?
|
Genetic Predisposition to Disease | 7 | 2021 | 18074 | 0.280 |
Why?
|
Proto-Oncogene Proteins | 1 | 2019 | 4520 | 0.280 |
Why?
|
Histones | 1 | 2017 | 2590 | 0.270 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2053 | 0.270 |
Why?
|
Alphapapillomavirus | 1 | 2009 | 219 | 0.270 |
Why?
|
Hamartoma | 1 | 2009 | 235 | 0.270 |
Why?
|
Lipoma | 2 | 2019 | 294 | 0.260 |
Why?
|
Paranasal Sinuses | 1 | 2009 | 267 | 0.260 |
Why?
|
HMGA2 Protein | 2 | 2017 | 101 | 0.260 |
Why?
|
Mitotic Index | 2 | 2018 | 160 | 0.250 |
Why?
|
Oxyphil Cells | 2 | 2019 | 55 | 0.250 |
Why?
|
Adenoma | 1 | 2016 | 2155 | 0.250 |
Why?
|
Respiratory Mucosa | 1 | 2009 | 437 | 0.250 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2021 | 614 | 0.250 |
Why?
|
Adolescent | 20 | 2022 | 88811 | 0.240 |
Why?
|
DNA Methylation | 2 | 2023 | 4424 | 0.230 |
Why?
|
Adamantinoma | 1 | 2023 | 9 | 0.220 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2017 | 335 | 0.220 |
Why?
|
Transcription Factors | 4 | 2024 | 12129 | 0.220 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4111 | 0.210 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15401 | 0.210 |
Why?
|
Cell Nucleus | 3 | 2016 | 2864 | 0.200 |
Why?
|
Tumor Burden | 3 | 2021 | 1888 | 0.200 |
Why?
|
Genital Neoplasms, Male | 1 | 2022 | 68 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2838 | 0.190 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2022 | 103 | 0.190 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2795 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.180 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20133 | 0.180 |
Why?
|
Sarcoma, Kaposi | 1 | 2024 | 376 | 0.180 |
Why?
|
Limbus Corneae | 1 | 2022 | 144 | 0.180 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2020 | 91 | 0.170 |
Why?
|
Oncogene Fusion | 1 | 2020 | 84 | 0.170 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3183 | 0.170 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 246 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9373 | 0.160 |
Why?
|
Submandibular Gland | 1 | 2019 | 84 | 0.160 |
Why?
|
Retinoblastoma-Binding Protein 1 | 1 | 2018 | 137 | 0.160 |
Why?
|
Phenotype | 5 | 2021 | 16714 | 0.160 |
Why?
|
Receptor, trkC | 1 | 2018 | 63 | 0.150 |
Why?
|
Synaptophysin | 1 | 2018 | 137 | 0.150 |
Why?
|
Child | 12 | 2022 | 80568 | 0.150 |
Why?
|
Patient Care | 1 | 2024 | 628 | 0.150 |
Why?
|
DNA, Viral | 2 | 2019 | 2196 | 0.150 |
Why?
|
Kidney Neoplasms | 1 | 2015 | 4278 | 0.150 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2895 | 0.150 |
Why?
|
Human papillomavirus 18 | 1 | 2018 | 125 | 0.150 |
Why?
|
Fibroma, Ossifying | 2 | 2020 | 14 | 0.140 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2018 | 60 | 0.140 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2017 | 41 | 0.140 |
Why?
|
Receptor, Notch1 | 2 | 2017 | 516 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 483 | 0.140 |
Why?
|
Genital Neoplasms, Female | 1 | 2022 | 534 | 0.140 |
Why?
|
Prognosis | 8 | 2017 | 29890 | 0.140 |
Why?
|
Laryngeal Neoplasms | 2 | 2018 | 513 | 0.140 |
Why?
|
Fibronectins | 1 | 2020 | 720 | 0.140 |
Why?
|
Cross Reactions | 1 | 2018 | 824 | 0.130 |
Why?
|
Antibody Specificity | 1 | 2018 | 1061 | 0.130 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2020 | 540 | 0.130 |
Why?
|
Dermatofibrosarcoma | 1 | 2016 | 49 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 360 | 0.130 |
Why?
|
Retrospective Studies | 14 | 2022 | 81537 | 0.130 |
Why?
|
Translocation, Genetic | 2 | 2018 | 1393 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2016 | 82 | 0.120 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2016 | 115 | 0.120 |
Why?
|
Adrenal Glands | 1 | 2017 | 556 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 998 | 0.120 |
Why?
|
Ascitic Fluid | 1 | 2014 | 189 | 0.110 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 561 | 0.110 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2018 | 328 | 0.110 |
Why?
|
Cyclin D1 | 2 | 2016 | 449 | 0.110 |
Why?
|
Neck | 1 | 2018 | 735 | 0.110 |
Why?
|
Sclerosis | 1 | 2013 | 211 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3599 | 0.100 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 323 | 0.100 |
Why?
|
Immunoenzyme Techniques | 1 | 2016 | 1695 | 0.100 |
Why?
|
Tissue Array Analysis | 2 | 2015 | 544 | 0.100 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2012 | 27 | 0.100 |
Why?
|
Pattern Recognition, Automated | 1 | 2018 | 979 | 0.100 |
Why?
|
Neuroendocrine Tumors | 1 | 2018 | 655 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 2969 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 723 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1195 | 0.100 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2013 | 237 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3158 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 99 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2019 | 1621 | 0.090 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2036 | 0.090 |
Why?
|
Chondrosarcoma | 1 | 2014 | 301 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.090 |
Why?
|
Leiomyosarcoma | 1 | 2015 | 425 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2885 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2945 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2019 | 5300 | 0.090 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2010 | 56 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11858 | 0.090 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 521 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2014 | 1072 | 0.080 |
Why?
|
Hashimoto Disease | 1 | 2011 | 108 | 0.080 |
Why?
|
Colon | 1 | 2017 | 1796 | 0.080 |
Why?
|
Risk | 2 | 2011 | 9599 | 0.080 |
Why?
|
Cohort Studies | 5 | 2019 | 41680 | 0.080 |
Why?
|
Neoplasm Metastasis | 3 | 2014 | 4882 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2014 | 1613 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5782 | 0.080 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2592 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1763 | 0.070 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3592 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2021 | 65194 | 0.060 |
Why?
|
Cell Differentiation | 3 | 2022 | 11639 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6838 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2014 | 1469 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1882 | 0.060 |
Why?
|
Survival Rate | 3 | 2017 | 12822 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2009 | 1250 | 0.060 |
Why?
|
Child, Preschool | 4 | 2022 | 42510 | 0.050 |
Why?
|
Leukoplakia, Oral | 1 | 2024 | 79 | 0.050 |
Why?
|
Quality Improvement | 1 | 2018 | 3847 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2027 | 0.050 |
Why?
|
Parotid Gland | 1 | 2024 | 177 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1362 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11196 | 0.050 |
Why?
|
Thyroidectomy | 2 | 2019 | 912 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7073 | 0.050 |
Why?
|
Vimentin | 1 | 2022 | 257 | 0.050 |
Why?
|
Databases, Factual | 2 | 2014 | 8060 | 0.050 |
Why?
|
Risk Assessment | 2 | 2019 | 24275 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13631 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3940 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2022 | 3684 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2010 | 1659 | 0.040 |
Why?
|
Infant | 3 | 2022 | 36426 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 568 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 419 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 241 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2019 | 313 | 0.040 |
Why?
|
Skull Base | 1 | 2021 | 293 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6503 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11090 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2019 | 228 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17531 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4641 | 0.040 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2024 | 921 | 0.030 |
Why?
|
Immunotherapy | 2 | 2024 | 4746 | 0.030 |
Why?
|
United States | 3 | 2021 | 72909 | 0.030 |
Why?
|
Gadolinium | 1 | 2021 | 966 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21069 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 344 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2016 | 254 | 0.030 |
Why?
|
Head | 1 | 2021 | 926 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1272 | 0.030 |
Why?
|
Cornea | 1 | 2022 | 1315 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2120 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1950 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1104 | 0.030 |
Why?
|
Health Facilities | 1 | 2019 | 577 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2611 | 0.030 |
Why?
|
Medical Records | 1 | 2019 | 1408 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12405 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3430 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9525 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 74850 | 0.030 |
Why?
|
Nephrectomy | 1 | 2017 | 927 | 0.030 |
Why?
|
Metaphase | 1 | 2012 | 143 | 0.020 |
Why?
|
Colectomy | 1 | 2017 | 697 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2701 | 0.020 |
Why?
|
Chromosome Breakage | 1 | 2012 | 159 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 40097 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3542 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1156 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2012 | 302 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1411 | 0.020 |
Why?
|
Cell Shape | 1 | 2012 | 372 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8603 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 570 | 0.020 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2010 | 52 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 2012 | 437 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39228 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2016 | 1117 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4335 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54807 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3537 | 0.020 |
Why?
|
Fibroblasts | 1 | 2020 | 4161 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1276 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 956 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2206 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7193 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2017 | 10426 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5330 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9239 | 0.020 |
Why?
|
Chromatin | 1 | 2020 | 2979 | 0.020 |
Why?
|
Urothelium | 1 | 2009 | 275 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2022 | 18962 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3530 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3796 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6542 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10086 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9334 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6058 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2009 | 789 | 0.010 |
Why?
|
Lymphoma | 1 | 2011 | 1896 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26380 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26282 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5880 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8492 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17596 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14064 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21513 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8522 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36547 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23597 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 16039 | 0.010 |
Why?
|